Biotech Values

[DewDiligence]

ASBM—…there's always going to be caveats in projecting pre-clinical data forward to the clinic.

True, but it’s a matter of degree. For ASMB’s HBV program, the scientific underpinning for what they hope to accomplish (curing HBV patients with a short course of 2-DAA therapy, as can be done in HCV) strikes me as unusually tenuous.

ASBM's calculations regarding the rate of natural decay of HBV cccDNA are based on subtracting a poorly-defined duration from another poorly-defined duration, which results in a number that's even more poorly defined that the two input values.